Search research articles
Contact Us
Filters
Showing results (61-70 of 130) with videos related to
Page
of 13
Sort By:
Environmental Toxicology and Chemistry
|
April 21, 2005
Metamorphic inhibition of Xenopus laevis by sodium perchlorate: effects on development and thyroid histology
Joseph E Tietge, Gary W Holcombe, Kevin M Flynn, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 18, 2025
Transforming the Evaluation of Agrochemicals: A Conceptual Model
Bhuller Yadvinder, Bishop Patricia, Cope Rhian, et al.
Digestive Diseases and Sciences
|
April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease
Sarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Inflammatory Bowel Diseases
|
December 23, 2017
Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
Anita Afzali, Matthew A Ciorba, David A Schwartz, et al.
Toxicologic Pathology
|
May 10, 2008
Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice
Douglas C Wolf, Tanya Moore, Barbara D Abbott, et al.
Contemporary Clinical Trials
|
October 8, 2022
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
Brian G Feagan, Stefan Schreiber, Anita Afzali, et al.
Toxicologic Pathology
|
May 21, 2009
Best practices for use of historical control data of proliferative rodent lesions
Charlotte Keenan, Susan Elmore, Sabine Francke-Carroll, et al.
Gastro Hep Advances
|
August 12, 2024
Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry
Douglas C Wolf, April N Naegeli, Page C Moore, et al.
Gastroenterology
|
November 9, 2011
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
William J Sandborn, Gert van Assche, Walter Reinisch, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 21, 2019
Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible
John E Doe, Alan R Boobis, Vicki Dellarco, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 130) with videos related to
Sort By:
Page
of 13
Environmental Toxicology and Chemistry
|
April 21, 2005
Metamorphic inhibition of Xenopus laevis by sodium perchlorate: effects on development and thyroid histology
Joseph E Tietge, Gary W Holcombe, Kevin M Flynn, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 18, 2025
Transforming the Evaluation of Agrochemicals: A Conceptual Model
Bhuller Yadvinder, Bishop Patricia, Cope Rhian, et al.
Digestive Diseases and Sciences
|
April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease
Sarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Inflammatory Bowel Diseases
|
December 23, 2017
Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
Anita Afzali, Matthew A Ciorba, David A Schwartz, et al.
Toxicologic Pathology
|
May 10, 2008
Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice
Douglas C Wolf, Tanya Moore, Barbara D Abbott, et al.
Contemporary Clinical Trials
|
October 8, 2022
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
Brian G Feagan, Stefan Schreiber, Anita Afzali, et al.
Toxicologic Pathology
|
May 21, 2009
Best practices for use of historical control data of proliferative rodent lesions
Charlotte Keenan, Susan Elmore, Sabine Francke-Carroll, et al.
Gastro Hep Advances
|
August 12, 2024
Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry
Douglas C Wolf, April N Naegeli, Page C Moore, et al.
Gastroenterology
|
November 9, 2011
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
William J Sandborn, Gert van Assche, Walter Reinisch, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 21, 2019
Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible
John E Doe, Alan R Boobis, Vicki Dellarco, et al.
Page
of 13